Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases
International Journal of Radiation Oncology*Biology*Physics · 2025-08 · 122 (5) · 1292-1300
DOI: 10.1016/j.ijrobp.2025.03.015 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-08. Verfasst von Daniella Klebaner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stanford Cancer Institute, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Radiosurgery, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: We performed a dose escalation trial of hypofractionated stereotactic radiosurgery (SRS) to determine the maximum tolerated dose (MTD) of 3-fraction SRS for brain metastases resection cavities. METHODS AND MATERIALS: Following surgical resection of a brain metastasis, patients were enrolled by SRS treatment volume onto 2 arms: arm 1 = 4.2-14.1 cm3, approximating a 2 to 3 cm diameter sphere, and arm 2 = 14.2-33.5 cm3 or a 3 to 4 cm sphere equivalent. Dose escalation levels were 24, 27, 30, and 33 Gy in 3 consecutive-day fractions, with 6 patients at each dose level in a 6 + 6 trial design. Dose-limiting toxicity was defined as either acute (within 30 days of SRS) grade 3 to 5 central nervous system toxicity and/or late grade 3 to 5 radiation necrosis occurring at any subsequent timepoint. The MTD was defined as the highest dose where 0 to 1 out of 6 or 0 to 3 out of 12 had a dose-limiting toxicity. RESULTS: From 2009 to 2014, 48 evaluable patients were enrolled. One (2%) patient had acute G3 toxicity; dose escalation proceeded to 33 Gy. No MTD was reached. Overall, 14 (29%) of 48 patients had G1-4 late radiation necrosis; G1 in 4 (8%), G2 in 6 (13%), G3 in 2 (4%), and G4 in 2 (4%). At the 33 Gy dose level, any grade necrosis was 58% in all 12 patients, 83% in the 6 patients on the larger volume arm 2; no G3-4 necrosis occurred in smaller arm 1 targets. With a median overall survival of 24 months (95% CI, 18-35), the 1-year cumulative incidence rates were: 10% (95% CI, 3.8-21) for local progression, 48% (95% CI, 33-61) for distant intracranial progression, and 13% (95% CI, 5-24) for radiation necrosis. Nodular meningeal disease occurred in 15% (7 of 48) of patients. CONCLUSIONS: Grade 3 to 4 toxicity was 8% and no MTD was reached with dose escalation to 33 Gy in 3 fractions. However, with a 58% incidence of G1-4 radiation necrosis at the 33 Gy level and 33% G3-4 necrosis at 30 Gy on arm 2, a 3-fraction dose of 27-30 Gy for targets 2 to 3 cm and 27 Gy for targets 3 to 4 cm may provide the optimal balance between toxicity and tumor control. A dose of 33 Gy is reserved for cavities
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Stanford Cancer Institute, Stanford University, Stanford, California.
- Department of Neurosurgery, Stanford University, Stanford, California.
- Department of Radiation Oncology, Santa Clara Valley Medical Center, Santa Clara, California.
- Department of Radiation Oncology, Stanford Cancer Institute, Stanford University, Stanford, California. Electronic address: sgsoltys@stanford.edu.
Zitieren
APA
Klebaner, D., Pollom, E. L., Rahimy, E., Gibbs, I. C., Adler, J. R., Chang, S. D., Li, G., Choi, C. Y. H., & Soltys, S. G. (2025). Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases. International Journal of Radiation Oncology*Biology*Physics, 122(5), 1292-1300. https://doi.org/10.1016/j.ijrobp.2025.03.015
Vancouver
Klebaner D, Pollom EL, Rahimy E, Gibbs IC, Adler JR, Chang SD, et al. Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 2025;122(5):1292-1300. doi:10.1016/j.ijrobp.2025.03.015
BibTeX
@article{Klebaner2025,
author = {Klebaner, Daniella and Pollom, Erqi L and Rahimy, Elham and Gibbs, Iris C and Adler, John R and Chang, Steven D and Li, Gordon and Choi, Clara Y H and Soltys, Scott G},
title = {Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
volume = {122},
number = {5},
pages = {1292--1300},
doi = {10.1016/j.ijrobp.2025.03.015}
}
EUVIMED